Sol-Gel Technologies Ltd.'s SEC filings document the disclosure record of a foreign private issuer developing and partnering dermatology drug products. Form 6-K reports include operating and financial results, unaudited condensed financial statements, clinical and regulatory updates for SGT-610, SGT-210 and EPSOLAY, and material-event disclosures incorporated by reference into the company's Form S-8 and Form F-3 registration statements.
The filings also cover shareholder meeting materials, auditor appointments, board elections, interim executive leadership approvals under Israeli corporate governance requirements, and capital-structure matters involving the company's ordinary shares. These documents frame Sol-Gel's public-company reporting around dermatology pipeline development, approved topical products, licensing arrangements, governance actions, and financing capacity.
Opaleye Management Inc. reported open market purchases of Sol-Gel Technologies Ltd. (SLGL) ordinary shares. On 11/24/2025, an affiliated fund bought 6 ordinary shares at $35.5 per share, and on 11/26/2025 it bought another 943 shares at a weighted average price of $40.00. Following these transactions, the fund is shown as beneficially owning 364,100 Sol-Gel ordinary shares, with an additional 10,000 shares held in a separately managed account. Opaleye Management Inc. states that it may be deemed to beneficially own these securities through its roles with the fund and the managed account and disclaims beneficial ownership except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd. (SLGL) director Opaleye Management Inc. reported buying additional ordinary shares. On 11/20/2025, an affiliated fund purchased 5,784 ordinary shares at a weighted average price of $35.8305 per share in multiple trades within a price range of $35.132 to $36.10. After this transaction, Opaleye Management Inc. reports indirect beneficial ownership of 363,151 ordinary shares through Opaleye, L.P. and 10,000 ordinary shares through a separately managed account. The firm states it may be deemed to beneficially own these securities as investment manager and portfolio manager, while disclaiming beneficial ownership beyond its economic interest.
Sol-Gel Technologies Ltd. (SLGL) submitted a Form 6-K reporting that it issued a press release on November 20, 2025 announcing its financial results for the quarter ended September 30, 2025. The filing mainly serves to furnish this press release to investors.
Most of the press release, identified as Exhibit 99.1 (other than the two paragraphs immediately preceding the heading “Financial Results for the Third Quarter 2025”), is incorporated by reference into the company’s Registration Statements on Form S-8 (Registration Nos. 333-223915, 333-270477 and 333-286820) and its Registration Statement on Form F-3 (Registration No. 333-286822).
Sol-Gel Technologies Ltd. (SLGL) received an initial ownership report from Opaleye Management Inc. as a 10% owner. The filing shows indirect beneficial ownership of 357,367 ordinary shares through Opaleye, L.P. and 10,000 ordinary shares through a separately managed account. Opaleye Management Inc. states it may be deemed to beneficially own these securities as investment manager and portfolio manager, but expressly disclaims beneficial ownership beyond its economic interest.
Sol-Gel Technologies Ltd. furnished a Notice of its 2025 Annual General Meeting and an accompanying proxy statement, together with a proxy card for shareholders of record as of September 29, 2025. The materials are incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, ensuring the proxy disclosures are available to holders eligible to vote and to support related securities registrations. This filing supplies the formal voting materials shareholders need to review meeting matters and to submit proxies ahead of the meeting.
Sol-Gel Technologies Ltd. filed a report noting that it has received Health Canada approval for EPSOLAY®. This approval, announced in a company press release, represents official clearance for the product in the Canadian market. The filing also states that portions of the press release are incorporated by reference into Sol-Gel’s existing registration statements on Form S-8 and Form F-3, linking the product approval to the company’s broader capital markets documentation.
Opaleye Management Inc., Opaleye, L.P. and James Silverman reported beneficial ownership of 139,386 ordinary shares of Sol-Gel Technologies Ltd (SLGL), representing 5.00% of the class based on 2,785,787 shares outstanding. The shares are held by the Fund with voting and dispositive power shared among the reporting persons; no sole voting or dispositive power is reported. The filing states the stake was not acquired to change or influence control of the issuer and includes a joint filing agreement signed by James Silverman.
Sol-Gel Technologies Ltd. submitted a Form 6-K reporting two exhibits: a press release dated August 15, 2025 and unaudited condensed consolidated financial statements as of June 30, 2025 covering the three- and six-month periods ended June 30, 2025. The filing amends and restates the incorporation-by-reference language so that Exhibit 99.1 (except for four paragraphs immediately preceding the financial-results heading) and Exhibit 99.2 are incorporated into the company’s registration statements on Forms S-8 and F-3. The report is signed by the Chief Financial Officer, indicating the exhibits are being furnished to the SEC and made available to investors and registrants relying on the referenced registration statements.